We have started a clinical trial with a new antidiskinetic therapy (combination of two drugs already authorized in other indications) to evaluate its safety and efficacy in patients with severe dyskinesia in advanced Parkinson’s disease. The aim is to study a safer therapy and with a lower risk than the invasive therapies currently used .
Evaluation of an inhibitor of the LRRK 2 gene in Parkinson’s patients. Oral tract. We…
Trial on LRRK2 mutation in Parkinson’s disease is about to be completed. Our Clinical Trials…
Highly positive results from the pivotal Phase III BouNDless trial evaluating ND0612 in patients with…
The new formulation of inhaled levodopa, Inbrija, has been approved for marketing in Spain. Manufactured…
The FDA has approved the use of sublingual apomorphine (KYNMOBI) in motor blocks, in Parkinson’s…
An intranasal levodopa has been authorized in the US to treat off blockages, called Inbrija….
Levodopa infusion pump We evaluate an ultraconcentrated levodopa administered subcutaneously in patients with motor fluctuations….
Our Unit has achieved to be activated in this outstanding project and so serious pathology….
Más idiomas
ES / EN / CAT son las versiones oficiales revisadas.
